{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-058706","form_type":"8-K","ticker":"ELDN","cik":"0001404281","company_name":"Eledon Pharmaceuticals, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.267520+00:00","generated_at":"2026-06-02T02:03:24.331649+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Eledon Q1 net loss $10.3M ($0.34/share); cash $42.9M; $50M private placement","bullets":["Net loss of $10.3M ($0.34 diluted EPS) vs $10.8M loss ($0.75 EPS) in Q1 2023.","Cash, cash equivalents & short-term investments $42.9M at quarter end, excluding $50M private placement.","Completed oversubscribed $50M private placement at $2.37/share with institutional investors.","First patient dosed in investigator-led islet cell transplant trial with tegoprubart for type 1 diabetes.","Phase 2 BESTOW trial (tegoprubart vs tacrolimus) enrolled 12th participant; full enrollment expected end 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-058706","json":"https://secwatch.observer/filing/0000950170-24-058706.json","markdown":"https://secwatch.observer/filing/0000950170-24-058706.md","text":"https://secwatch.observer/filing/0000950170-24-058706.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404281/000095017024058706/0000950170-24-058706-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404281/000095017024058706/eldn-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:03:24.331649+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ce99eed66999164f121535dcca543c01501c16f6","claim":"Eledon Pharmaceuticals, Inc. reported the quarter ended March 31, 2024 results: net income net loss of $10.3 million, EPS $0.34 per share.","evidence_excerpt":"The Company reported a net loss of $10.3 million, or $0.34 per share, for the three months ended March 31, 2024, compared to a net loss of $10.8 million, or $0.75 per share, for the same period in 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404281/000095017024058706/0000950170-24-058706-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Net income","value":"net loss of $10.3 million"},{"label":"EPS","value":"$0.34 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}